Literature DB >> 33298295

A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program.

Anthony DeFulio1, Mark J Rzeszutek2, Josh Furgeson3, Shawn Ryan4, Samin Rezania4.   

Abstract

Contingency management (CM) is an efficacious incentive-based intervention for promoting drug abstinence, but treatment providers have not widely adopted it. Smartphone and smart debit card technologies can deliver automated, patient-centered, high-fidelity CM and related services, including cognitive behavioral therapy and appointment reminders. This study evaluated clinical outcomes associated with an integrated smartphone-smartcard platform in an inner-city outpatient clinic. We enrolled adults with opioid use disorder (n = 85) over nine weeks, and they received CM services for four months. We retrospectively compared them to matched controls who received services at the same time, from the same provider at a similar, nearby clinic in the same city. The platform was associated with significantly higher rates of counseling appointment attendance in study months 2 to 4 (9.6%-18.0% increases) and an odds ratio of 4.84 for increased proportion of urine samples consistent with drug abstinence and adherence to prescribed medication, compared to controls at 120 days (P < 0.05). Overwhelmingly, participants reported that they found the platform acceptable. These results suggest that the platform is an effective method for remote delivery of CM services that could overcome key logistical barriers to widespread adoption of CM among treatment providers.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Cognitive behavioral therapy; Contingency management; Incentives; Ohio; Opioid use disorder

Mesh:

Year:  2020        PMID: 33298295     DOI: 10.1016/j.jsat.2020.108188

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  8 in total

1.  A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth.

Authors:  Amanda M Palmer; Rachel L Tomko; Lindsay M Squeglia; Kevin M Gray; Matthew J Carpenter; Tracy T Smith; Jennifer Dahne; Benjamin A Toll; Erin A McClure
Journal:  Drug Alcohol Depend       Date:  2022-01-19       Impact factor: 4.492

2.  Acceptability and Usability of a Reward-Based Mobile App for Opioid Treatment Settings: Mixed Methods Pilot Study.

Authors:  Steven L Proctor; Khary K Rigg; Allen Y Tien
Journal:  JMIR Form Res       Date:  2022-10-05

3.  Rewarding recovery: the time is now for contingency management for opioid use disorder.

Authors:  Steven L Proctor
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

4.  A randomized controlled trial of contingency management for smoking cessation in substance use treatment patients.

Authors:  Roberto Secades-Villa; Gema Aonso-Diego; Alba González-Roz
Journal:  Int J Clin Health Psychol       Date:  2022-05-26

5.  Smartphone-based incentives for promoting adherence to antiretroviral therapy: A randomized controlled trial.

Authors:  Anthony DeFulio; Amanda Devoto; Haily Traxler; David Cosottile; Michael Fingerhood; Paul Nuzzo; Jesse Dallery
Journal:  Prev Med Rep       Date:  2021-01-07

Review 6.  Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.

Authors:  Mary M Sweeney; August F Holtyn; Maxine L Stitzer; David R Gastfriend
Journal:  Psychiatr Clin North Am       Date:  2022-07-31

7.  Could COVID expand the future of addiction research? Long-term implications in the pandemic era.

Authors:  Amir Englund; Stephen Sharman; Basak Tas; John Strang
Journal:  Addiction       Date:  2022-01-25       Impact factor: 7.256

8.  A Smartphone-Smartcard Platform for Implementing Contingency Management in Buprenorphine Maintenance Patients With Concurrent Stimulant Use Disorder.

Authors:  Anthony DeFulio; Joshua Furgeson; Hayley D Brown; Shawn Ryan
Journal:  Front Psychiatry       Date:  2021-12-07       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.